Céleste J T van der Togt

6PUBLICATIONS
10CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Disease surveillanceClinical pharmacology and therapeuticsToxicology (incl. clinical toxicology)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 18, 2026
Subcutaneous versus intravenous ultra-low dose rituximab in rheumatoid arthritis: a randomised controlled PK-PD non-inferiority trial.

|Feb 12, 2024
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study.

Céleste J T van der Togt, Nathan den Broeder, Marleen S Boonstra

|Mar 02, 2023
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.

Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha

|Dec 19, 2022
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study).

Céleste J T van der Togt, Lise M Verhoef, Bart J F van den Bemt

|Aug 24, 2022
Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.

Céleste J T van der Togt, David F Ten Cate, Bart J F van den Bemt

|Apr 04, 2022
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis.

Céleste J T van der Togt, David F Ten Cate, Nathan den Broeder

Pageof 1

Frequent Collaborators

2 joint publications

Nathan den Broeder

1 joint publications

Daniel Aletaha

1 joint publications

Rieke Alten

1 joint publications

Katerina Chatzidionysiou